The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Effectiveness of the BNT162b2 Covid-19 Vaccine against the B.1.1.7 and B.1.351 Variants
Open accessAbstract
The messenger RNA vaccine BNT162b2 (Pfizer–BioNTech) has 95% efficacy against coronavirus disease 2019 (Covid-19). Qatar launched a mass immunization campaign with this vaccine on December 21, 2020. As of March 31, 2021, a total of 385,853 persons had received at least one vaccine dose and 265,410 had completed the two doses. Vaccination scale-up occurred as Qatar was undergoing its second and third waves of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, which were triggered by expansion of the B.1.1.7 variant (starting in mid-January 2021) and the B.1.351 variant (starting in mid-February 2021). The B.1.1.7 wave peaked during the first week of March, and the rapid expansion of B.1.351 started in mid-March and continues to the present day. Viral genome sequencing conducted from February 23 through March 18 indicated that 50.0% of cases of Covid-19 in Qatar were caused by B.1.351 and 44.5% were caused by B.1.1.7. Nearly all cases in which virus was sequenced after March 7 were caused by either B.1.351 or B.1.1.7.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“The test-negative design, which does not assume that a lack of a positive test equals a negative test and somewhat adjusts for testing volume, attempts to better mitigate this bias and is the reason we chose this method for this analysis”
From Waning effectiveness of the third dose of the BNT162b2 mRNA COVID-19 vaccine (2022) · cites this paper as [25]
In the citing paper
“Reduced protection against any symptomatic COVID-19 disease caused by the B.1.351 variant of concern (now known as the Beta variant) has been reported from clinical trials18, but emerging data suggest that there remains high protection against the important end points of severe disease and hospitalization99.”
From Immunological mechanisms of vaccine-induced protection against COVID-19 in humans (2021) · cites this paper as [99]
In the citing paper
“These inclusion and exclusion criteria were implemented to allow for build-up of immunity after vaccination4,14 and to minimize different types of potential bias, as informed by earlier analyses in the same population.”
From Effects of Previous Infection and Vaccination on Symptomatic Omicron Infections (2022) · cites this paper as [14]
In the citing paper
“Effectiveness was assessed with the use of an observational, test-negative, case–control design rather than a design in which cohorts of individual persons were followed up. However, the cohort study design applied earlier to the same population yielded findings similar to those of the test-negative design.14,15,31”
From Effects of Previous Infection and Vaccination on Symptomatic Omicron Infections (2022) · cites this paper as [14]
In the citing paper
“However, the cohort study design applied earlier to the same population of Qatar yielded findings similar to those of the test-negative case–control design36,38,39, supporting the validity of this standard approach in assessing vaccine effectiveness11,12,36,40.”
From Duration of mRNA vaccine protection against SARS-CoV-2 Omicron BA.1 and BA.2 subvariants in Qatar (2022) · cites this paper as [38]
In the citing paper
“As compared with recent findings from Qatar on the effectiveness of the BNT162b2 vaccine against the alpha and beta variants,17 our findings suggest that effectiveness against the delta variant after a full vaccination course lies somewhere between these two.”
From Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant (2021) · cites this paper as [17]
In the citing paper
“In cohort studies from Israel and Qatar, the BNT162b vaccine also retained greater than 90% efficacy against this variant 210,211 (TABLe 2).”
From The biological and clinical significance of emerging SARS-CoV-2 variants (2021) · cites this paper as [211]
In the citing paper
“In the previously cited Qatar cohort study, the efficacy of BNT162b against the Beta variant was estimated to be 72%, which was 15% lower than that for the Alpha variant 211 .”
From The biological and clinical significance of emerging SARS-CoV-2 variants (2021) · cites this paper as [211]
In the citing paper
“Likewise, clinical studies have reported somewhat reduced efficacy and effectiveness against the B.1.1.7, B.1.351, and B.1.617.2 variants (10–12).”
From Durability of mRNA-1273 vaccine–induced antibodies against SARS-CoV-2 variants (2021) · cites this paper as [10]
In the citing paper
“The effectiveness of the BNT162b2 vaccine against the Beta variant was measured shortly after the population of Qatar had been vaccinated, whereas the effectiveness of BNT162b2 against the Delta variant was conducted several months after the second dose, which could be one of the reasons for low effectiveness of BNT162b2 against the Delta variant.404,405”
From Advances in COVID-19 mRNA vaccine development (2022) · cites this paper as [405]
In the citing paper
“Beta [as a benchmark for partially reduced neutralization (7) without major impact on effectiveness (19, 20)]”
From Neutralization of SARS-CoV-2 Omicron by BNT162b2 mRNA vaccine–elicited human sera (2022) · cites this paper as [19]
In the citing paper
“Coronavirus disease 2019 (Covid-19) vaccines are highly effective against symptomatic disease and, more so, against severe disease and fatal outcomes caused by the original strain of SARS-CoV-2 as well as the alpha (B.1.1.7) variant that predominated in early 2021.”
From Effectiveness of COVID-19 vaccines against the Omicron (B.1.1.529) variant of concern (2021) · cites this paper as [15]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
Polack, F. P., Thomas, S. J., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J. L., Pérez Marc, G., Moreira, E. D., Zerbini, C., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2034577 · Cited by 14,592
BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting
Dagan, N., Barda, N., Kepten, E., Miron, O., Perchik, S., Katz, M. A., Hernán, M. A., Lipsitch, M., Reis, B., & Balicer, R. D. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2101765 · Cited by 2,527
Thompson, M. G., Burgess, J. L., Naleway, A. L., Tyner, H. L., Yoon, S. K., Meece, J., Olsho, L. E. W., Caban-Martinez, A. J., Fowlkes, A., Lutrick, K., et al. (2021) · MMWR. Morbidity and Mortality Weekly Report · doi:10.15585/mmwr.mm7013e3 · Cited by 707
The test-negative design for estimating influenza vaccine effectiveness
Jackson, M. L., & Nelson, J. C. (2013) · Vaccine · doi:10.1016/j.vaccine.2013.02.053 · Cited by 510
Flagged first, then by citations
Cited by
Sorted by citations
Items 501–600 of 879
Pacheco-Olvera, D. L., Remy-Hernández, S. S., García-Valeriano, M. G., Rivera-Hernández, T., & López-Macías, C. I. R. (2022) · Archives of Medical Research · doi:10.1016/j.arcmed.2022.10.007 · Cited by 12
Lind, M. L., Copin, R., McCarthy, S., Coppi, A. C., Warner, F., Ferguson, D. J. P., Duckwall, C., Borg, R., Muenker, M. C., Overton, J. D., et al. (2022) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiac453 · Cited by 13
Enhancing global preparedness during an ongoing pandemic from partial and noisy data
Klamser, P., d’Andrea, V., Lauro, F. D., Zachariae, A., Bontorin, S., Nardo, A. D., Hall, M. D., Maier, B. F., Luca Ferretti, A., Brockmann, D., et al. (2023) · PNAS Nexus · doi:10.1093/pnasnexus/pgad192 · Cited by 13
The Key Site Variation and Immune Challenges in SARS-CoV-2 Evolution
Liu, Y., & Ye, Q. (2023) · Vaccines · doi:10.3390/vaccines11091472 · Cited by 12
Takeshita, M., Nishina, N., Moriyama, S., Takahashi, Y., Ishii, M., Saya, H., Kondo, Y., Kaneko, Y., Suzuki, K., Fukunaga, K., et al. (2022) · Clinical Immunology · doi:10.1016/j.clim.2022.108999 · Cited by 12
Vaccines for Covid‐19: An insight on their effectiveness and adverse effects
Qamar, N., Rukh, G., & Khan, S. N. (2022) · Journal of Medical Virology · doi:10.1002/jmv.27810 · Cited by 12
Neutralizing Effect of Synthetic Peptides toward SARS-CoV-2
Souza, P. F. N., van Tilburg, M. F., Mesquita, F. P., Amaral, J. L., Lima, L. B., Montenegro, R. C., Lopes, F. E. S., Martins, R. X., Vieira, L., Farias, D. F., et al. (2022) · ACS Omega · doi:10.1021/acsomega.2c02203 · Cited by 12
SARS-CoV-2 Portrayed against HIV: Contrary Viral Strategies in Similar Disguise
Duerr, R., Crosse, K. M., Valero-Jimenez, A. M., & Dittmann, M. (2021) · Microorganisms · doi:10.3390/microorganisms9071389 · Cited by 12
Dalvie, N. C., Tostanoski, L. H., Rodriguez‐Aponte, S. A., Kaur, K., Bajoria, S., Kumru, O. S., Martinot, A. J., Chandrashekar, A., McMahan, K., Mercado, N. B., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.07.13.452251 · Cited by 12
SARS-CoV-2 vaccine effectiveness in immunosuppressed kidney transplant recipients
Chemaitelly, H., AlMukdad, S., Joy, J. P., Ayoub, H. H., Yassine, H. M., Benslimane, F. M., Al Khatib, H. A., Tang, P., Hasan, M. R., Coyle, P., et al. (2021) · doi:10.1101/2021.08.07.21261578 · Cited by 12
Self-citationRecent update on future therapeutic strategies for COVID-19 vaccination with omicron variant
Ellakwa, D. E., Elsheikh-Hassan, A. F., Ellakwa, T. E., & Abdelmalek, M. A. (2024) · Human Gene · doi:10.1016/j.humgen.2024.201281 · Cited by 11
Identifying SARS-CoV-2 Variants Using Single-Molecule Conductance Measurements
Aminiranjbar, Z., Gultakti, C. A., Alangari, M., Wang, Y., Demir, B., Koker, Z., Das, A., Anantram, M. P., Ören, E. E., & Hihath, J. (2024) · ACS Sensors · doi:10.1021/acssensors.3c02734 · Cited by 11
Living with COVID-19: The road ahead
Wei, W. E., Tan, W. K., Cook, A. R., Hsu, L. Y., Teo, Y. Y., & Lee, V. J. M. (2021) · Annals of the Academy of Medicine Singapore · doi:10.47102/annals-acadmedsg.2021244 · Cited by 11
Egeren, D. V., Stoddard, M., Novokhodko, A., Rogers, M. S., Joseph‐McCarthy, D., Zetter, B. R., & Chakravarty, A. (2021) · PLoS ONE · doi:10.1371/journal.pone.0258997 · Cited by 11
A Promising Vaccination Strategy against COVID-19 on the Horizon: Heterologous Immunization
Mattoo, S.-U.-S., & Myoung, J. (2021) · Journal of Microbiology and Biotechnology · doi:10.4014/jmb.2111.11026 · Cited by 11
Immunology and Technology of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Vaccines
Pecetta, S., Kratochvil, S., Kato, Y., Vadivelu, K., & Rappuoli, R. (2022) · Pharmacological Reviews · doi:10.1124/pharmrev.120.000285 · Cited by 11
Quantitation of SARS-CoV-2 neutralizing antibodies with a virus-free, authentic test
Roessler, J., Pich, D., Albanese, M., Wratil, P. R., Krähling, V., Hellmuth, J. C., Scherer, C., von Bergwelt‐Baildon, M., Becker, S., Keppler, O. T., et al. (2022) · PNAS Nexus · doi:10.1093/pnasnexus/pgac045 · Cited by 12
Nonhuman primate models for evaluation of SARS-CoV-2 vaccines
Neil, J. A., Griffith, M., Godfrey, D. I., Purcell, D. F. J., Deliyannis, G., Jackson, D. C., Rockman, S., Subbarao, K., & Nolan, T. M. (2022) · Expert Review of Vaccines · doi:10.1080/14760584.2022.2071264 · Cited by 11
Wang, B., Xu, J., Wu, S., Zhang, Z., Zhao, Z., Zhang, J., Fu, L. L., Zai, X., Wang, Y., Zhang, G., et al. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01065-0 · Cited by 11
Kim, J., Kim, D., Baek, K., Kim, M., Kang, B. M., Maharjan, S., Park, S., Choi, J.-K., Kim, S., Kim, Y. K., et al. (2022) · Viruses · doi:10.3390/v15010028 · Cited by 11
Gurjar, P., Karuvantevida, N. S., Rzhepakovsky, I. V., Khan, A. A., & Khandia, R. (2023) · Vaccines · doi:10.3390/vaccines11020487 · Cited by 11
Zhang, J., Yang, W., Huang, F., & Zhang, K. (2023) · Journal of Medical Virology · doi:10.1002/jmv.28623 · Cited by 11
Hejazi, N. S., Shen, X., Carpp, L. N., Benkeser, D. C., Follmann, D. A., Janes, H., Baden, L. R., Sahly, H. M. E., Deng, W., Zhou, H., et al. (2023) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2023.09.012 · Cited by 11
Kobayashi, K., Tachibana, M., & Tsutsumi, Y. (2021) · Innate Immunity · doi:10.1177/17534259211043159 · Cited by 11
Liu, J., Bodnar, B. H., Padhiar, N. H., Khan, A. I., Meng, F., Saribas, S., Wang, P., Wang, X., McCluskey, E., Shah, S., et al. (2021) · Clinical and Translational Medicine · doi:10.1002/ctm2.644 · Cited by 11
Pereira, M., Oh, J. K., Kang, D., Engstrand, L. G., & Valeriano, V. D. (2022) · BioTech · doi:10.3390/biotech11010003 · Cited by 11
Cortés-Sarabia, K., Gutiérrez-Torres, M., Mendoza-Renteria, E. M., Leyva‐Vázquez, M. A., Vences-Velázquez, A., Hernández‐Sotelo, D., Beltrán‐Anaya, F. O., Moral-Hernández, Ó. D., & Illades‐Aguiar, B. (2022) · Vaccines · doi:10.3390/vaccines10060909 · Cited by 12
Mucker, E. M., Brocato, R. L., Principe, L. M., Kim, R. K., Zeng, X., Smith, J. M., Kwilas, S. A., Kim, S., Horton, H., Caproni, L. J., et al. (2022) · Vaccines · doi:10.3390/vaccines10071104 · Cited by 11
A SARS-CoV-2: Companion Animal Transmission and Variants Classification
Pandit, R., & Matthews, Q. L. (2023) · Pathogens · doi:10.3390/pathogens12060775 · Cited by 11
Comprehensive Understanding and Field Application of COVID-19 Vaccine
Choi, W. S. (2021) · Korean Journal of Medicine · doi:10.3904/kjm.2021.96.3.155 · Cited by 11
Hauser, B. M., Sangesland, M., Lam, E. C., Denis, K. S., Feldman, J. E., Yousif, A. S., Caradonna, T. M., Kannegieter, T., Balazs, A. B., Lingwood, D., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.12.07.415216 · Cited by 11
Evaluation of mRNA-1273 against SARS-CoV-2 B.1.351 Infection in Nonhuman PrimatesPreprint
Corbett, K. S., Werner, A. P., Connell, S. O., Gagné, M., Lai, L., Moliva, J. I., Flynn, B. J., Choi, A., Koch, M. J., Foulds, K. E., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.05.21.445189 · Cited by 11
Kim, Y.-J., Kim, E., Lee, S., & Kwon, D. (2021) · Osong Public Health and Research Perspectives · doi:10.24171/j.phrp.2021.0037 · Cited by 10
Durability and expansion of neutralizing antibody breadth following Ad26.COV2.S vaccination of mice
Mahrokhian, S. H., Tostanoski, L. H., Jacob-Dolan, C., Zahn, R. C., Wegmann, F., McMahan, K., Yu, J., Gebre, M. S., Bondzie, E. A., Wan, H., et al. (2022) · npj Vaccines · doi:10.1038/s41541-022-00454-4 · Cited by 10
Solís-Andrade, K. I., González‐Ortega, O., Govea‐Alonso, D. O., Comas‐García, M., & Rosales‐Mendoza, S. (2022) · Vaccines · doi:10.3390/vaccines10101759 · Cited by 10
Al‐Rifai, R. H., Hosani, F. I. A., Abuyadek, R. M., Atef, S. H., Donnelly, J. G., Leinberger‐Jabari, A., Ahmed, L. A., Altrabulsi, B., Alatoom, A. A., Alsuwaidi, A. R., et al. (2023) · Frontiers in Medicine · doi:10.3389/fmed.2022.1092646 · Cited by 10
Hernandez, N. E., Jankowski, W., Frick, R., Kelow, S. P., Lubin, J. H., Simhadri, V. L., Adolf‐Bryfogle, J., Khare, S. D., Dunbrack, R. L., Gray, J. J., et al. (2023) · Heliyon · doi:10.1016/j.heliyon.2023.e15032 · Cited by 10
SARS-CoV-2 S1 Subunit Booster Vaccination Elicits Robust Humoral Immune Responses in Aged Mice
Kim, E., Khan, M. S., Ferrari, A., Huang, S., Sammartino, J. C., Percivalle, E., Kenniston, T. W., Cassaniti, I., Baldanti, F., & Gambotto, A. A. (2023) · Microbiology Spectrum · doi:10.1128/spectrum.04363-22 · Cited by 10
Meeraus, W. H., Joy, M., Ouwens, M., Taylor, K., Venkatesan, S., Dennis, J., Tran, T. N., Dashtban, A., Fan, X., Williams, R., et al. (2024) · Journal of Infection · doi:10.1016/j.jinf.2024.106129 · Cited by 12
An Antigenic Space Framework for Understanding Antibody Escape of SARS-CoV-2 Variants
Miller, N. L., Clark, T., Raman, R., & Sasisekharan, R. (2021) · Viruses · doi:10.3390/v13102009 · Cited by 10
mRNA vaccine-a desirable therapeutic strategy for surmounting COVID-19 pandemic
Chen, P., Shi, X., He, W., Zhong, G., Tang, Y., Wang, H., & Zhang, P. (2022) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2022.2040330 · Cited by 10
Hu, L., Xu, Y., Wu, L., Feng, J., Zhang, L., Tang, Y., Zhao, X., Mai, R., Chen, L., Mei, L., et al. (2022) · Viruses · doi:10.3390/v14050854 · Cited by 11
Vacunación contra SARS-CoV-2 y su relación con enfermedad y muerte por COVID-19 en Argentina
Scruzzi, G. F., Aballay, L. R., Carreño, P., Rousseau, G. A. D., Franchini, C. G., Cecchetto, E., Willington, A. P., Barbás, M. G., & López, L. (2022) · Revista Panamericana de Salud Pública · doi:10.26633/rpsp.2022.39 · Cited by 10
Luminescent Assay for the Screening of SARS‐CoV‐2 MPro Inhibitors
Sondag, D., Merx, J., Rossing, E., Boltje, T. J., Löwik, D. W. P. M., Nelissen, F. H. T., van Geffen, M., Veer, C. V. ′., van Heerde, W. L., & Rutjes, F. P. J. T. (2022) · ChemBioChem · doi:10.1002/cbic.202200190 · Cited by 10
Panahi, Y., Einollahi, B., Beiraghdar, F., Darvishi, M., Fathi, S., Javanbakht, M., Shafiee, S., & Akhavan‐Sigari, R. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.947602 · Cited by 10
Mbarek, H., & Ismail, S. I. (2022) · Nature Genetics · doi:10.1038/s41588-022-01239-0 · Cited by 10
Sivadas, N., Panda, P., & Mahajan, A. (2022) · IEEE Transactions on Computational Social Systems · doi:10.1109/tcss.2022.3210404 · Cited by 11
Ding, Y., Fan, F., Xu, X., Zhao, G., Zhang, X., Zhao, H., Wang, L., Wang, B., & Gao, X.-M. (2023) · Vaccines · doi:10.3390/vaccines11040778 · Cited by 10
Jantarabenjakul, W., Chantasrisawad, N., Puthanakit, T., Wacharapluesadee, S., Hirankarn, N., Ruenjaiman, V., Paitoonpong, L., Suwanpimolkul, G., Torvorapanit, P., Pradit, R., et al. (2021) · medRxiv · doi:10.1101/2021.08.27.21262721 · Cited by 10
COVID-19 Anti-Vaccine Sentiments in Malaysia: Narratives of Comments from Facebook Post
Wong, L. P., Alias, H., Wong, Y., Hashim, M. M. A. A. M., Lin, Y., & Hu, Z. (2023) · Vaccines · doi:10.3390/vaccines11040834 · Cited by 9
An Appraisal of the Current Scenario in Vaccine Research for COVID-19
Chong, W. C., Chellappan, D. K., Shukla, S. D., Peterson, G. M., Patel, R. P., Jha, N. K., Eri, R. D., Dua, K., Tambuwala, M. M., & Shastri, M. D. (2021) · Viruses · doi:10.3390/v13071397 · Cited by 9
Diotallevi, F., Campanati, A., Radi, G., Martina, E., Rizzetto, G., Barbadoro, P., D’Errico, M. M., & Offidani, A. (2021) · Dermatology and Therapy · doi:10.1007/s13555-021-00610-z · Cited by 9
The Emergence of the New P.4 Lineage of SARS-CoV-2 With Spike L452R Mutation in Brazil
Bittar, C., Possebon, F. S., Ullmann, L. S., Geraldini, D. B., da Costa, V. G., de Almeida, L. G. P., Sanches, P. R. D. S., Nascimento-Júnior, N. M., Cilli, E. M., Banho, C. Á., et al. (2021) · Frontiers in Public Health · doi:10.3389/fpubh.2021.745310 · Cited by 10
BNT162b2-elicited neutralization of Delta plus, Lambda, Mu, B.1.1.519, and Theta SARS-CoV-2 variants
Liu, J., Liu, Y., Xia, H., Zou, J., Weaver, S. C., Swanson, K. A., Cai, H., Cutler, M. W., Cooper, D., Muik, A., et al. (2022) · npj Vaccines · doi:10.1038/s41541-022-00462-4 · Cited by 9
Hoang, H. T., Nguyen, X. T. K., Huynh, V.-S., Hua, T. D., Tran, H. T. T., & Tran-Chi, V.-L. (2022) · Frontiers in Psychology · doi:10.3389/fpsyg.2022.968902 · Cited by 9
Zhou, Y., Li, G., Zhao, T., Du, J., Zhang, W., Xie, M., Chen, L., Zeng, J., Wang, C., Liu, B., et al. (2022) · Journal of Medical Virology · doi:10.1002/jmv.28256 · Cited by 9
Tian, W., Ren, X., Han, M., Zhang, Y., Gao, X., Chen, Z., & Zhang, W. (2022) · International Journal of Immunopathology and Pharmacology · doi:10.1177/03946320221141802 · Cited by 9
Butt, A. A., Guerrero, M. D., Canlas, E. B., Al-Dwairi, H., Alimam, A., Mohamad, A. R., Ali, M. T., Asaad, N., Alkeldi, A. A. S. S., Mohammad, M. F. S., et al. (2023) · Nature Communications · doi:10.1038/s41467-022-35653-z · Cited by 9
Self-citationButt, A. A., Peng, Y., Shaikh, O. S., Talisa, V. B., Omer, S. B., & Mayr, F. (2023) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiad393 · Cited by 9
Self-citationHumoral and cellular immunity against diverse SARS-CoV-2 variants
Chen, C., Wang, X., & Zhang, Z. (2023) · Journal of genetics and genomics/Journal of Genetics and Genomics · doi:10.1016/j.jgg.2023.10.003 · Cited by 10
Vaccinating against a Novel Pathogen: A Critical Review of COVID-19 Vaccine Effectiveness Evidence
Black, B. S., & Thaw, D. B. (2023) · Microorganisms · doi:10.3390/microorganisms12010089 · Cited by 9
An EKF prediction of COVID-19 propagation under vaccinations and viral variants
Zhu, X., Shi, Y., & Zhong, Y. (2024) · Mathematics and Computers in Simulation · doi:10.1016/j.matcom.2024.12.012 · Cited by 9
Boni, C., Cavazzini, D., Bolchi, A., Rossi, M., Vecchi, A. L., Tiezzi, C., Barili, V., Fisicaro, P., Ferrari, C. I., & Ottonello, S. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.730051 · Cited by 9
Diverse vaccine platforms safeguarding against SARS-CoV-2 and its variants
Chatterjee, B., & Thakur, S. S. (2021) · Expert Review of Vaccines · doi:10.1080/14760584.2022.1997601 · Cited by 9
Reactogenicity to COVID-19 vaccination in the United States of America
Sanyaolu, A. O., Marinkovic, A., Prakash, S., Desai, P., Haider, N., Abbasi, A. F., Mehraban, N., Jain, I., Ekeh, A., Shazley, O., et al. (2022) · Clinical and Experimental Vaccine Research · doi:10.7774/cevr.2022.11.1.104 · Cited by 9
Zhao, J., Zhu, J., Huang, C., Zhu, X., Zhu, Z., Wu, Q., & Yuan, R. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1035151 · Cited by 9
mRNA Vaccine Mitigates SARS-CoV-2 Infections and COVID-19
Kackos, C. M., Surman, S. L., Jones, B. G., Sealy, R. E., Jeevan, T., Davitt, C. J. H., Pustylnikov, S., Darling, T. L., Boon, A. C. M., Hurwitz, J. L., et al. (2023) · Microbiology Spectrum · doi:10.1128/spectrum.04240-22 · Cited by 9
Preclinical evaluation of PHH-1V vaccine candidate against SARS-CoV-2 in non-human primates
Prenafeta, A., Bech-Sàbat, G., Moros, A., Barreiro, A., Fernández, A., Cañete, M., Roca, M., González‐González, L., Garriga, C., Confais, J., et al. (2023) · iScience · doi:10.1016/j.isci.2023.107224 · Cited by 9
Shah, J. N., Samson, P., Pradhan, N. M. S., Maharjan, S., Shrestha, A., Shah, J., Shah, J., & Sarala, K. C. (2021) · Journal of Patan Academy of Health Sciences · doi:10.3126/jpahs.v8i2.37287 · Cited by 9
Ng, Ö. H., Akyoney, S., Sahin, I., Soykam, H. O., Akçapınar, G. B., Özdemir, Ö., Kançağı, D. D., Karakuş, G. S., Yurtsever, B., Kocagöz, S., et al. (2021) · PLoS ONE · doi:10.1371/journal.pone.0260438 · Cited by 10
Uwamino, Y., Yokoyama, T., Shimura, T., Nishimura, T., Sato, Y., Wakui, M., Kosaki, K., Hasegawa, N., & Murata, M. (2022) · Vaccine · doi:10.1016/j.vaccine.2022.02.047 · Cited by 9
SARS-CoV-2 variants of concern dominate in Lahore, Pakistan in April 2021
Sarwar, M. B., Yasir, M., Alikhan, N.-F., Afzal, N., Martins, L. D. O., Le-Viet, T., Trotter, A. J., Prosolek, S. J., Kay, G. L., Foster-Nyarko, E., et al. (2021) · Microbial Genomics · doi:10.1099/mgen.0.000693 · Cited by 9
COVID-19 Vaccination Strategies and Their Adaptation to the Emergence of SARS-CoV-2 Variants
Stefanelli, P., & Rezza, G. (2022) · Vaccines · doi:10.3390/vaccines10060905 · Cited by 10
Evolution of Anti-SARS-CoV-2 IgG Antibody and IgG Avidity Post Pfizer and Moderna mRNA VaccinationsPreprint
Bliden, K. P., Liu, T., Sreedhar, D., Kost, J., Hsiung, J., Zhao, S., Shan, D., Usman, A., Walia, N., Cho, A., et al. (2021) · medRxiv · doi:10.1101/2021.06.28.21259338 · Cited by 10
Rodrigues, E. F., Moreno, J., Leite, P. P., Casaca, P., Nunes, B., Gomes, J. P., Ferreira, R., Isidro, J., Borges, V., Vieira, L., et al. (2022) · medRxiv · doi:10.1101/2022.01.21.22268602 · Cited by 9
Slamanig, S., Lemus, N., Lai, T. Y., Singh, G., Mishra, M., Abdeljawad, A., Boza, M., Dolange, V., Singh, G., Lee, B., et al. (2024) · Vaccine · doi:10.1016/j.vaccine.2024.126586 · Cited by 8
Immunotherapy for neuroblastoma using mRNA vaccines
Ahmed, T. (2022) · Advances in Cancer Biology - Metastasis · doi:10.1016/j.adcanc.2022.100033 · Cited by 8
Albayat, S. S., Almaslamani, M., Al‐Romaihi, H. E., Khogali, H., Mundodan, J. M., Joury, J., & Haridy, H. (2023) · Vaccines · doi:10.3390/vaccines11050953 · Cited by 8
Sarkar, A., Santra, D., Panja, A. S., & Maiti, S. (2023) · International Immunopharmacology · doi:10.1016/j.intimp.2023.110636 · Cited by 8
Abbad, A., Yellin, T., Singh, G., Fried, M., Raskin, A. J., Tcheou, J., Monahan, B., Gleason, C., Andre, D., Bermúdez-González, M. C., et al. (2024) · Cell Reports Medicine · doi:10.1016/j.xcrm.2024.101474 · Cited by 8
Chemaitelly, H. S., Ayoub, H. H., Coyle, P. V., Tang, P., Hasan, M. R., Yassine, H. M., Thani, A. A. A., Kanaani, Z. A., Al‐Kuwari, E., Jeremijenko, A. M., et al. (2024) · Influenza and Other Respiratory Viruses · doi:10.1111/irv.13357 · Cited by 8
Self-citationZhang, C., Guo, Z., Li, N., Cui, H. Y., Meng, K., Liu, L., Zhao, L., Zhang, S., Qin, C., Liu, J., et al. (2021) · Frontiers in Microbiology · doi:10.3389/fmicb.2021.722178 · Cited by 8
Divergent Antibody Repertoires Found for Omicron versus Wuhan SARS-CoV-2 Strains Using Ig-MS
Forte, E., Soye, B. J. D., Melani, R. D., Hollas, M. A. R., Kafader, J. O., Sha, B. E., Schneider, J. R., & Kelleher, N. L. (2022) · Journal of Proteome Research · doi:10.1021/acs.jproteome.2c00514 · Cited by 8
Jayathilaka, D., Jeewandara, C., Gomes, L., Jayadas, T. T. P., Kamaladasa, A., Somathilake, G., Guruge, D., Pushpakumara, P. D., Ranasinghe, T., Aberathna, I. S., et al. (2022) · Clinical & Experimental Immunology · doi:10.1093/cei/uxac009 · Cited by 9
Kitro, A., Sirikul, W., Thongkum, W., Soponpong, S., Yasamut, U., Kiratipaisarl, W., Kosai, A., Kasinrerk, W., Tayapiwatana, C., & Srithanaviboonchai, K. (2022) · Vaccine · doi:10.1016/j.vaccine.2022.04.020 · Cited by 8
Cushan‐Kain, G., Gardner, B., Verplanken, B., Lally, P. J., Rhodes, R. E., Kwaśnicka, D., Alfrey, K.-L. R., & Rebar, A. L. (2022) · Applied Psychology Health and Well-Being · doi:10.1111/aphw.12369 · Cited by 8
Recipients of COVID-19 vaccines face challenges of SARS-CoV-2 variants
Li, T., & Luo, K. Q. (2022) · International Journal of Biological Sciences · doi:10.7150/ijbs.72424 · Cited by 8
Deb, P., Molla, M. M. A., Saif‐Ur‐Rahman, K., Das, M. C., & Das, D. (2021) · Egyptian Journal of Bronchology · doi:10.1186/s43168-021-00090-x · Cited by 7
Liang, J., Yuan, H., Li, K., Wei, W.-I., Wong, S. Y. S., Tang, A., Riley, S., & Kwok, K. O. (2022) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2022.07.048 · Cited by 7
Magnus, M. C., Håberg, S. E., Carlsen, E. Ø., Kwong, J. C., Buchan, S. A., & Fell, D. B. (2022) · Clinical Infectious Diseases · doi:10.1093/cid/ciac739 · Cited by 7
In Vitro Anti-SARS-CoV-2 Activities of Curcumin and Selected Phenolic Compounds
Razak, M. R. M. A., Jelas, N. H. M., Muhammad, A., Padlan, N., Sa’at, M. N. F., Azizan, M. A., Rosli, S. N. Z., Ellan, K., Zainol, M., Thayan, R., et al. (2023) · Natural Product Communications · doi:10.1177/1934578x231188861 · Cited by 7
Xu, K., Li, J., Xu, L., Ge, X., Wang, K., Wang, J., Qiao, Z., Quan, Y., & Li, C. (2024) · Vaccines · doi:10.3390/vaccines12010060 · Cited by 7
The Psychological Gains from COVID-19 Vaccination: Who Benefits the Most?
Bagues, M. F., & Dimitrova, V. (2021) · Journal of Public Economics · doi:10.1016/j.jpubeco.2025.105304 · Cited by 8
Chakraborty, C., Lo, Y.-H., Bhattacharya, M., Das, A., & Wen, Z. (2025) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2025.102527 · Cited by 8
Tande, A. J., Pollock, B. D., Shah, N. D., Binnicker, M. J., & Berbari, E. F. (2021) · Infection Control and Hospital Epidemiology · doi:10.1017/ice.2021.399 · Cited by 7
Robilotti, E. V., Whiting, K. A., Bianchi, A. L., Poon, C., Guest, R., McMillen, T. A., Jani, K., Solovyov, A., Kelson, S., Browne, K., et al. (2021) · Clinical Infectious Diseases · doi:10.1093/cid/ciab886 · Cited by 7
Kim, P. S., Schildhouse, R. J., Saint, S. K., Bradley, S., Chensue, S. W., Houchens, N., & Gupta, A. B. (2021) · American Journal of Infection Control · doi:10.1016/j.ajic.2021.10.003 · Cited by 7
Karim, M. A., Reagu, S. M., Ouanes, S., Khan, A. W., Smidi, W. S., Al-Baz, N., & Alabdulla, M. (2022) · Medicine · doi:10.1097/md.0000000000029741 · Cited by 7
The Real-World Impact of Vaccination on COVID-19 Cases During Europe’s Fourth Wave
Jain, V., Serisier, A., & Lorgelly, P. K. (2022) · International Journal of Public Health · doi:10.3389/ijph.2022.1604793 · Cited by 7
Haque, M. A., Tanbir, M., Ahamed, B., Hossain, M. J., Roy, A., Shahriar, M., Bhuiyan, M. A., & Islam, M. R. (2023) · Clinical Pathology · doi:10.1177/2632010x231161222 · Cited by 7
Metadata
- Authors
- Abu-Raddad, L. J., Chemaitelly, H., & Butt, A. A.
- Affiliations
- Weill Cornell Medical College in Qatar (QA)
- Hamad Medical Corporation (QA)
- Corresponding author
- Abu-Raddad, Laith J.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2021-07-08
- Volume
- 385
- Issue
- 2
- Pages
- 187-189
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC8117967
- OpenAlex
- W3157162195
- Cited by
- 899
- References
- 4
- Citations by year
- 2026: 16 · 2025: 32 · 2024: 46 · 2023: 92 · 2022: 358 · 2021: 351
- FWCI
- 67.15
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Qatar University QSpace (Qatar University) (submittedVersion)
- Funders
- Biomedical Research Program and the Biostatistics, Epidemiology, and Biomathematics Research Core, both at Weill Cornell Medicine-Qatar, the Ministry of Public Health and Hamad Medical Corporation
- Topics
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Social Sciences › Health › Vaccine Coverage and Hesitancy
- Physical Sciences › Mathematics › Modeling and Simulation › COVID-19 epidemiological studies
- Keywords
- BNT162b2, COVID-19 vaccine efficacy, SARS-CoV-2 variants, B.1.1.7 variant, B.1.351 variant, Omicron variant, vaccination campaigns, viral genome sequencing, COVID-19 waves
- MeSH terms
- Immunogenicity, Vaccine, COVID-19, SARS-CoV-2, COVID-19 Vaccines, BNT162 Vaccine, Humans, Qatar, Cohort Studies, Case-Control Studies, Polymerase Chain Reaction, Treatment Outcome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
